Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471067 · ClinicalTrials.gov registry record · Phase 1
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01471067: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01471067 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01471067, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if it is safe and feasible to transplant changed cord blood for patients with leukemia or lymphoma. Researchers also want to learn if this can help to control the disease. The cord blood will be changed to make use of sugar that is found in small amounts in blood cells. It plays a role in signaling where in the body the transplanted cells should go to. Adding more sugars to the cord blood cells in the laboratory is designed to help the cord blood cells find their way faster to the bone marrow. This may help your blood counts to recover faster. This process is called fucosylation. Anti-thymocyte globulin (ATG) is a protein that removes immune cells that cause damage to the body. Clofarabine is designed to interfere with the growth and development of cancer cells. Fludarabine is designed to interfere with the DNA (genetic material) of cancer cells, which may cause the cancer cells to die. This chemotherapy is also designed to block your body's ability to reject the donor's bone marrow cells. Melphalan and busulfan are designed to bind to the DNA of cells, which may cause cancer cells to die. Mycophenolate mofetil (MMF) and tacrolimus are designed to block the donor cells from growing and spreading in a way that could cause graft versus host disease (GVHD -- a condition in which transplanted tissue attacks the recipient's body). This may help to prevent GVHD. Rituximab is designed to attach to cancer cells, which may cause them to die.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- PROCEDURE Cord Blood Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-07-13 |
| Est. Completion | 2017-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471067
The ClinicalTrials.gov registry entry for NCT01471067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01471067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01471067 about?
NCT01471067 is a clinical study titled "Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies". The goal of this clinical research study is to learn if it is safe and feasible to transplant changed cord blood for patients with leukemia or lymphoma. Researchers also want to learn if this can help to control the disease. The cord blood will be changed to make use of sugar that is found in small...
What is the current status of trial NCT01471067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-07-13. Estimated completion is 2017-04-25.
What interventions are being tested in trial NCT01471067?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), Cord Blood Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01471067?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.